Digital Trends Editor-In-Chief Jeremy Kaplan Interviews Panna Sharma Digital Trends Editor-in-Chief Jeremy Kaplan interviews Panna Sharma, President and CEO of Lantern Pharma, about the role of AI in precision medicine.
A Pioneering New Clinical Trial on a Drug that Could Potentially Help Millions of Men A pioneering new clinical trial on a drug that could potentially help millions of men with prostate cancer, is under way in Derry. Tumour samples from men being treated locally are being collated to test the drug’s effectiveness [...]
Global Precision Medicine Market Research Report - 2025 Top Companies Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the [...]
Lantern Pharma Announces Multiple Presentations at AACR 2019 FOR IMMEDIATE RELEASE Friday, March 29 - 2019 Lantern Pharma announces multiple presentations at AACR 2019 highlighting advancements of its precision oncology pipeline of therapeutics using their AI-based platform, RADR™,to identify gene signatures that predict potential response of patient’s tumor to a drug. [...]
No Longer Artificial – AI in Pharma and Healthcare AI firm Lantern Pharma has joined Genomics England’s ground-breaking 100,000 Genomes Project industry partnership to advance the role of AI in precision medicine.
Precision Oncology Company Lantern Pharma's Artificial Intelligence Approach NEW YORK--(BUSINESS WIRE)--Lantern Pharma is applying Artificial Intelligence (AI) to tailor multiple promising precision drug programs to the right cancer patients through use of their RADRTM platform (Response Algorithm for Drug Rescue and Positioning).
DALLAS--(BUSINESS WIRE)--Genomics England and Lantern Pharma, a clinical stage pharma company specializing in precision oncology using artificial intelligence, announced today that Lantern will join Genomics England’s Discovery Forum industry partnership. The partnership aims to translate groundbreaking research into innovative treatments, and ultimately patient benefit, as rapidly as possible.
When the Precision Medicine Initiative was announced by President Obama in 2015, he said: “delivering the right treatments, at the right time, every time, to the right person.” As the next heralded breakthrough in healthcare, simply put it is the ultra-tailored therapy.